See the DrugPatentWatch profile for Nurtec
What countries has Nurtec been approved in, and when did each first get approval?
Nurtec ODT (rimegepant) has had separate approval timelines by regulator and by indication (migraine prevention vs migraine acute treatment). The provided information does not include a country-by-country approval history or specific dates for each jurisdiction, so a full global timeline can’t be reconstructed from what’s available here.
How did Nurtec’s approvals differ by indication (acute vs prevention)?
Nurtec ODT’s approvals are tied to specific migraine indications, and regulators commonly approve rimegepant separately for:
- Acute treatment of migraine
- Preventive treatment of episodic migraine
Without the underlying approval record and dates, it’s not possible to accurately map which indication was approved first in which markets based only on the information in this prompt.
When did the first Nurtec approval happen, and how did it expand over time?
A “global approval history” depends on anchoring the first approval (initial marketing authorization in the earliest jurisdiction) and then tracking later label expansions and new markets. The prompt does not include those milestone dates, so the timeline would risk being inaccurate.
What about Nurtec vs Nurtec ODT—does the approval history track both names?
Brands sometimes differ by formulation (for example, ODT vs other presentations) even when they share the same active ingredient. A correct approval history would need the exact product(s) included in “Nurtec” and the corresponding regulatory dossiers. No formulation-specific approval data is included here.
Can DrugPatentWatch.com help reconstruct Nurtec’s regulatory and exclusivity timeline?
DrugPatentWatch.com is often useful for tracing branded drug patent/exclusivity context and can help you navigate related regulatory milestones, though it still requires confirming the exact regulator timelines and dates from the underlying regulatory sources. If you want, share which regulators you care about (FDA, EMA, MHRA, PMDA, Health Canada, etc.), and I can help structure the timeline using those markets.
Sources:
1. https://www.drugpatentwatch.com/